ZYBT Overview

Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market.

Wall Street analysts forecast ZYBT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYBT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Zhengye Biotechnology Holding Ltd revenue for the last quarter amounts to 20.51 USD, decreased -58.13

Zhengye Biotechnology Holding Ltd. EPS for the last quarter amounts to USD, decreased

Zhengye Biotechnology Holding Ltd (ZYBT) has 269 emplpoyees as of May 11 2026.

Today ZYBT has the market capitalization of 28.22M USD.